-transparent.png){kind=logo}
Thirty-three adult patients with solid tumors were treated with menogaril, a new anthracycline antibiotic. The drug was given as a two-hour infusion every 4 to 5 weeks at doses ranging from 17 to 250 mg/m2. The maximum tolerated dose was 250 mg/m2. Reversible and dose-related leukopenia was the dose-limiting toxicity. Thrombocytopenia was less frequent. Hematologic toxicity was maximal 2 weeks after treatment, and recovery usually occurred within 4 weeks. There was no dissociation between WBC and neutrophil counts, and myelosuppression did not appear to be cumulative up to 200 mg/m2. Myelosuppression was more severe for patients with heavy pretreatment and/or bone marrow involvement. Local toxicity consisting of phlebitis and/or erythema was the most common nonhematologic toxicity, especially at 250 mg/m2 (eight out of nine patients). Usually, erythema appeared within 24 hours after treatment at or near the infusion site and resolved within a few days. Occasionally, a more persistent (several weeks) orange discoloration suggesting cutaneous deposits of menogaril was observed. Nausea and vomiting were uncommon and never severe. Alopecia and mucositis were rare. Minor arrhythmias were seen in several patients during treatment, but their relationship with menogaril therapy was unclear, and in no patient did heart failure develop. Plasma concentrations were best described by a tricompartmental model with a mean terminal half-life of 29.5 hours and a mean total-body clearance of 20.2 L/h/m2. Doses of 160 and 200 mg/m2 are recommended for phase II trials in poor- and good-risk patients, respectively.
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
May 1992,
Annals of oncology : official journal of the European Society for Medical Oncology,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
February 1990,
Investigational new drugs,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
December 1989,
American journal of clinical oncology,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
January 1988,
Acta oncologica (Stockholm, Sweden),
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
June 1987,
Cancer treatment reports,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
August 1970,
The American surgeon,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
June 1986,
Cancer treatment reports,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
June 1988,
European journal of cancer & clinical oncology,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
February 1993,
Investigational new drugs,
P Dodion, and
C Sessa, and
R Joss, and
N Crespeigne, and
Y Willems, and
M Kitt, and
J Abrams, and
C Finet, and
J E Brewer, and
W J Adams
August 2004,
Clinical cancer research : an official journal of the American Association for Cancer Research,
